Physician profile
Ann E Henderson
NPI 1720054620
$14,149.04
in general payments reported to CMS, 2019-2025
72 companies · $1,876 in 2025
The $1,876 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,965 · 2022: $3,543 · 2023: $4,545 · 2024: $2,220 · 2025: $1,876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,089 · Education: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,088.65 |
| Education | $552.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,254.04 | 2021-2025 | Darzalex, Talvey, Tecvayli |
| Novartis Pharmaceuticals Corporation | $1,101.17 | 2021-2025 | |
| Daiichi Sankyo INC. | $634.04 | 2022-2025 | Enhertu, Injectafer, Vanflyta |
| Merck Sharp & Dohme LLC | $627.96 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $542.43 | 2021-2025 | |
| Seagen INC. | $521.81 | 2021-2023 | Tivdak, Tukysa, Adcetris |
| Alexion Pharmaceuticals, INC. | $475.31 | 2022-2025 | Ultomiris, Strensiq, Soliris |
| Pfizer INC. | $409.38 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $404.32 | 2021-2023 | Pomalyst, Opdivo, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $395.30 | 2021-2025 | Calquence, Enhertu, Imfinzi |
| Eisai INC. | $389.33 | 2021-2025 | |
| Puma Biotechnology, INC. | $348.54 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $327.96 | 2021-2024 | Alunbrig, Fruzaqla |
| Rigel Pharmaceuticals, INC. | $327.39 | 2021-2024 | Rezlidhia, Tavalisse |
| Genentech USA, INC. | $303.07 | 2021-2025 | Tecentriq, Gavreto, Rozlytrek |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $282.60 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Lilly USA, LLC | $265.57 | 2021-2024 | Jaypirca, Verzenio, Retevmo |
| Incyte Corporation | $256.30 | 2022-2023 | Jakafi, Monjuvi, Pemazyre |
| Celgene Corporation | $241.04 | 2021-2023 | Pomalyst, Reblozyl |
| Genzyme Corporation | $240.38 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $230.94 | 2021-2025 | Libtayo |
| Aveo Pharmaceuticals, INC. | $220.53 | 2022-2024 | Fotivda |
| Sobi, INC | $220.37 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $216.16 | 2021-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $214.13 | 2021-2023 | Imbruvica |
| Exelixis INC. | $175.16 | 2021-2025 | Cabometyx |
| Sage Therapeutics, LLC | $173.51 | 2025 | |
| Pharmaessentia USA Corporation | $170.64 | 2022-2024 | Besremi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.44 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $127.61 | 2021-2024 | Tazverik, Somatuline Depot, Onivyde |
| Adc Therapeutics America, INC. | $126.19 | 2022-2023 | |
| Beigene USA, INC. | $124.44 | 2022-2024 | Brukinsa |
| Mirati Therapeutics, INC. | $123.51 | 2023-2024 | Krazati |
| Ars Pharmaceuticals Operations, INC. | $121.69 | 2025 | Neffy |
| Alkermes, INC. | $120.00 | 2025 | Lybalvi |
| Teva Pharmaceuticals USA, INC. | $120.00 | 2025 | |
| Taiho Oncology, INC. | $118.77 | 2022-2024 | |
| Coloplast Corp | $111.66 | 2023 | Titan |
| Horizon Therapeutics Plc | $109.99 | 2023 | Uplizna |
| Global Blood Therapeutics, INC. | $108.92 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $108.18 | 2025 | |
| Morphosys, US INC. | $105.07 | 2021-2023 | Monjuvi |
| Axsome Therapeutics, INC. | $104.58 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $101.01 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $96.59 | 2022-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $96.00 | 2023 | |
| Insmed, INC. | $93.48 | 2025 | Arikayce |
| Astellas Pharma US INC | $90.46 | 2021-2024 | Xospata |
| Kite Pharma, INC. | $71.01 | 2023 | Yescarta |
| Recordati_rare_diseases_inc. | $70.70 | 2023-2024 | Sylvant |
| Genmab U.S., INC. | $67.94 | 2023 | Epkinly |
| Karyopharm Therapeutics INC. | $66.55 | 2022-2024 | Xpovio |
| Kyowa Kirin, INC. | $61.75 | 2023-2024 | Poteligeo |
| Stemline Therapeutics INC. | $60.44 | 2023 | Orserdu |
| Array Biopharma INC | $57.61 | 2023-2024 | Mektovi, Braftovi, Lorbrena |
| Immunogen, INC. | $53.66 | 2023 | Elahere |
| Gilead Sciences, INC. | $49.35 | 2023-2024 | |
| Servier Pharmaceuticals LLC | $45.30 | 2021-2022 | |
| Epizyme, INC. | $41.87 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $38.10 | 2021-2024 | Givlaari |
| Myriad Genetic Laboratories, INC. | $35.07 | 2022-2025 | Myrisk |
| Shield Therapeutics INC | $28.46 | 2024 | |
| Janssen Scientific Affairs, LLC | $23.07 | 2023 | Tecvayli, Darzalex |
| Agios Pharmaceuticals, INC. | $22.99 | 2024 | Pyrukynd |
| Pharmacosmos Therapeutics INC. | $22.05 | 2022 | |
| Blueprint Medicines Corporation | $20.70 | 2021 | |
| G1 Therapeutics, INC. | $19.43 | 2023 | Cosela |
| Adaptive Biotechnologies Corporation | $18.95 | 2024 | Clonoseq |
| Emd Serono, INC. | $17.89 | 2024 | |
| Tersera Therapeutics LLC | $14.30 | 2021 | |
| Novocure INC. | $13.97 | 2024 | Optune Lua (Novottf-200t) |
| Deciphera Pharmaceuticals INC. | $12.91 | 2022 |
Drugs and devices associated with these payments
Lybalvi $480Keytruda $336Enhertu $328Darzalex $311Tecvayli $240Talvey $231Kisqali $214Pomalyst $201Imbruvica $199Doptelet $198Tavalisse $193Rezlidhia $193Fotivda $193Rybrevant $173Epkinly $170Libtayo $164Lenvima $160Injectafer $139Ultomiris $137Cabometyx $135Lynparza $126Krazati $124Neffy $122Jevtana $121Leqvio $118Elahere $113Scemblix $112Titan $112Venclexta $110Uplizna $110Pluvicto $108Ingrezza $108Strensiq $105Auvelity $105Besremi $104Quviviq $101Soliris $101Erleada $99.12Arikayce $93.48Tukysa $92.90Oxbryta $90.53Jaypirca $87.33Verzenio $87.33Calquence $85.36Lorbrena $77.57Carvykti $76.32Jakafi $73.89Lonsurf $73.13Inqovi $73.13Retevmo $71.64Ojjaara $71.29Sylvant $70.70Tivdak $67.49Zejula $66.10Ibrance $62.79Poteligeo $61.75Adcetris $61.53Orserdu $60.44Brukinsa $60.29Mektovi $57.61Braftovi $57.61Piqray $56.49Welireg $53.98Lutathera $53.13Tazverik $52.02Nubeqa $51.96Xofigo $51.96Yescarta $48.19Inlyta $42.74Monjuvi $41.59Avastin $41.11Gavreto $41.11Tecentriq $41.11Rozlytrek $41.11Xalkori $39.89Eliquis $39.42Polivy $36.41Xospata $33.84Jemperli $33.31Promacta $30.44Bosulif $30.14Elrexfio $30.14Accrufer $28.46Padcev $27.69Alunbrig $27.01Xarelto $26.63Givlaari $26.40Xpovio $26.34Alecensa $24.14Fruzaqla $23.89Reblozyl $23.82Vanflyta $23.47Pyrukynd $22.99Xtandi $22.78Talzenna $22.78Lunsumio $22.42Columvi $22.42Opdivo $22.37Enjaymo $21.63Tasigna $21.34
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.